This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-12. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Ádám István Mechler is a materials scientist and academic most known for his research on intermolecular interactions in physical chemistry, as well as on molecular machines, hierarchical metamaterials, and self-assembling systems inspired by biology. He is a professor of Chemistry at La Trobe University, Australia, where he leads the Bioinspired self-assembling nanostructures research group. He is also the Academic Program Director of the IIT Kanpur - La Trobe University Research Academy and the BITS Pilani - La Trobe University joint PhD program.
=== Zubrin's planet mastery === In Entering Space: Creating a Spacefaring Civilization, Robert Zubrin suggests another form: his definition of a Type I civilization is described as one that has achieved full mastery of the resources of its planet (global), a Type II of its solar system (interplanetary), and a Type III would have unleashed the full potential of the galaxy (starfaring civilization). Metrics other than pure energy consumption have also been proposed. He ponders the possibility of a Type IV civilization, one that would dominate the universe, noting that there are limits to how minds can connect and interact on a galactic or intergalactic basis. As an example, he mentions that communication from the Galactic Center of the Milky Way galaxy to its edge would take about 50,000 years (since nothing can travel faster than light, according to our understanding of physics).
Some mammalian species and subspecies of Portugal such as red deer, Iberian ibex, wild boar, red fox, Iberian wolf, and Iberian lynx were once widespread throughout the country, but intense hunting, habitat degradation, and growing pressure from agriculture and livestock largely reduced their populations in the 19th and 20th centuries. There are three mammalian species and subspecies, such as the Portuguese ibex that became extinct, but some mammalian species, such as the Iberian hare, have been re-expanding their native range.
=== Francis Crick Graduate Lectures === The University of Cambridge Graduate School of Biological, Medical and Veterinary Sciences hosts The Francis Crick Graduate Lectures. The first two lectures were by John Gurdon and Tim Hunt.
Sources: en.wikipedia.org
The spot indole test is used to determine if a microbe can deaminate tryptophan to produce indole. This test is performed by saturating a piece of filter paper with Indole Kovacs Reagent and scraping a portion of microbe onto the paper. A color to a pink-red color indicates a positive result while no color change indicates the lack of tryptophanase.
PfSSM (2008), CBM and CCF (2008) for Plasmodium proteins, which have a different amino acid evolutionary bias due to the low GC content of the genome. Matrices for transmembrane proteins. JTT transmembrane (1994) is the first of the class. Later work include: For alpha-helical transmembrane proteins, PHAT (2000) and SLIM (2001). For beta-barrel transmembrane proteins, bbTM (2008). Matrices for a specific protein family, including GPCRtm (2015) for the transmembrane (mostly helical) regions of GPCRs. Matrices for proteins with a specific role, including Hubsm (2017) for "hub proteins" in protein‐protein interaction networks. Matrices for intrinsically disordered proteins, including DUNMat (2002), MidicMat (2009), Disorder (2010), and EDSSMat (2019).
=== February === On February 1, the 68th Annual Grammy Awards were held. Kendrick Lamar and SZA won Record of the Year and Best Melodic Rap Performance for "Luther". Olivia Dean won Best New Artist. Kehlani won Best R&B Performance and Best R&B Song for "Folded". Leon Thomas won Best Traditional R&B Performance for "Vibes Don't Lie" and Best R&B Album for Mutt. Durand Bernarr won Best Progressive R&B Album for Bloom. Samara Joy won Best Jazz Vocal Album for Portrait. Mariah Carey received the MusiCares Person of the Year award. Pharrell Williams received the Dr. Dre Global Impact Award. Brandy and Kirk Franklin received the Black Music Icon Award. Whitney Houston and Chaka Khan received the Lifetime Achievement Award. On February 3, Lamonte McLemore died at the age of 90. On February 11, Janet Jackson's Rhythm Nation 1814 by Janet Jackson, "Trouble in Mind" by Bertha Hill, "Jesus Gave Me Water" by The Soul Stirrers, and Maggot Brain by Funkadelic were inducted into the Grammy Hall of Fame. On February 28, John P. Hammond died at the age of 83. On the same day, the 57th NAACP Image Awards were held. 803Fresh and Fantasia won Outstanding Duo, Group or Collaboration (Traditional) for "Boots on the Ground (Remix)". Chris Brown, Bryson Tiller and Usher won Outstanding Soul/R&B Song and Outstanding Duo, Group or Collaboration (Contemporary) for "It Depends". Tyla won Outstanding International Song for "Is It". Kendrick Lamar and SZA won Outstanding Music Video/Visual Album for "Luther".
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.